Benchmark analyst Robert Wasserman initiated coverage of Repligen with a Buy rating and $230 price target. The company was one of the primary beneficiaries of the demand for COVID-19 vaccines, diagnostics and therapeutics due to its "highly innovative bioprocessing technologies," said the analyst, who notes that Repligen’s recent product launches in support of new biotechnologies helped boost organic revenue growth to 39% in 2022 with the COVID-19 pandemic waning. The firm’s price target represents almost 40% potential share price appreciation, the analyst noted.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RGEN:
- Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
- Repligen price target lowered to $220 from $251 at Craig-Hallum
- Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
- Repligen sees FY23 adjusted EPS $2.61-$2.69, consensus $2.92
- Repligen reports Q4 adjusted EPS 68c, consensus 58c
